Epstein Files Search

EFTA01088033Set 9

2016-04-1921p9,988w

Biotechnology Bank of America e Growth at a reasonable price - How much Merrill Lynch are you paying for a pipeline? Industry Overview Equity 1 19 April 2016 Biotech trading meaningfully ... below historical averages United States Biotechnology The Nasdaq Biotechnology Index (NBI) has underperformed the broader market, down 17% vs the S&P 500 up 3% year-to-date. Since ... styles) Chart 2:Large cap managers' relative weight in Biotech. 9/08-present 1.4 2.0 Biotechnology 1.9 - 0 1.2 1.8 - Life Sciences Tools 8 Seances 1.7 1.1 1.6 Avg. OA4 in Biotech

https://www.justice.gov/epstein/files/DataSet%209/EFTA01088033.pdf

EFTA01092032Set 9

25p12,760w

Avenue New York, NY 10174 — SEE PAGE 25 FOR IMPORTANT DISCLOSURES AND DISCLAIMERS EFTA01092032 Biotechnology — Regenerative Medicine INVESTMENT SUMMARY I The discussion in regenerative medicine has more recently and increasingly ... SVFC product falls under an exemption to FDA regulation. Maxim Group LLC 2 EFTA01092033 Biotechnology — Regenerative Medicine The SVFC product and the procedures used for the product are similar ... patients with ischemic cardiomyopathy. 2012. JAMA 308(22). Maxim Group LLC 3 EFTA01092034 Biotechnology — Regenerative Medicine In addition, Mesoblast performed two pilot studies in cardiac and orthopedic indications in which

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf

EFTA01113381Set 9

8p2,027w

Chapter 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE NANOPARTICLES IN BIOTECHNOLOGY, DRUG DEVELOPMENT AND DRUG DELIVERY BIO113B August 2014 Jackson Highsmith Project Analyst ISBN ... toll-free within the USA), www.bccresearch.com EFTA01113381 810113B - Nanoparticles in Biotechnology, Drug Development and Drug Delivery CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE The global market for nanoparticles ... exhibiting double-digit increases in each period. TABLE 10 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2019 (S MILLIONS) CAGR% Application 2012 2013 2014 2019 2014-2019 Drug

https://www.justice.gov/epstein/files/DataSet%209/EFTA01113381.pdf

EFTA01100261Set 9

2016-02-2939p20,086w

initiate at EW with a $28 PT; Despite our LT optimism for the Biotechnology / United States of America Stock Rating Equal-weight promise of gene editing, two near-term headwinds ... Valuation Methodology: We prefer the use of a DCF analysis to value biotechnology companies. Given the defined patent life for each product, we believe a DCF fully captures both ... period as well as the long-term earnings power. While investors do look at biotechnology on a multiples basis (PIE), we prefer a DCF as it is more rigorous

https://www.justice.gov/epstein/files/DataSet%209/EFTA01100261.pdf

EFTA01192826Set 9

2015-05-2711p5,409w

Health Care RTRX.00 RTRX US NMS RTRX Price target 52.00 Biotechnology 52-week range 26.98 - 8.09 Agrees to sell PRV for $245M, new TP Robyn Karnauskas Research Anal ... ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 124/04/2015. EFTA01192826 27 May 2015 Biotechnology Retrophin Model updated:27 May 2015 Fiscal year end 31-Dec 2014 2016E 2018E 2017E ... Repatod EPSIUSD) 0.84 0.63 2.13 2.19 United States CPS IUSDI 0.00 0.00 0.00 0.00 Biotechnology BVPS (USDI -L49 Q07 7.88 9.86 [Valuation Metrics IRetrophin Price/Sales

https://www.justice.gov/epstein/files/DataSet%209/EFTA01192826.pdf

EFTA01473355Set 10

2015-05-2756p5,913w

Deutsche Bank Markets Research Rating Buy North America United States Reuters Health Care Biotechnology RTRX.OQ Bloomberg RTRX US Exchange Ticker NMS RTRX Company Retrophin Agrees to sell PRV for $245M ... ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 124/04/2015. EFTA01473357 27 May 2015 Biotechnology Retrophin Model updated:27 May 2015 Running the numbers North America United States Biotechnology Retrophin ... EFTA01473365 27 May 2015 Biotechnology Retrophin RTRX DCF Figure 1: RTRX DCF DB BIOTECH: RETROPHIN DCF Robyn Karnauskas PhD 212-250-7591, DB BIOTECH: RTRX - DISCOUNTED CASH FLOW 2015E

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01473355.pdf

EFTA01965146Set 10

3p490w

mary Driven, fast learning, and intellectually curious biotechnology student looking for field experience and further education. International backround, with a skill in, and love for working with others. Objective ... biomedical research. Education Palm Beach State College Palm Beach Gardens, FL Associate of Arts, Biotechnology 2009 — Present (anticipated completion date: 191h December, 2013) Czech Academy of Business Prague, Czech Republic ... Protein Yield & Purity Determination EFTA_R1_00442407 EFTA01965146 Relevant Coursework Introduction to Biotechnology Lecture & Laboratory •4. Biotechnology I. Genomics Lecture & Laboratory '0. Biotechnology II. Proteomics Lecture & Laboratory Principles of Biology

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01965146.pdf

EFTA01973784Set 10

2012-12-043p864w

Officer G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01973784.pdf

EFTA00718477Set 9

2012-12-042p761w

Officer G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US- Japan Science

https://www.justice.gov/epstein/files/DataSet%209/EFTA00718477.pdf

EFTA00956529Set 9

2013-03-147p5,347w

simply cannot In this Life Sciences Report interview. Jason Kolbert senior vice president and biotechnology analyst with Maxim Group. provides a detailed analysts of the industry and names companies that ... about it. Ram Setvaraju More a JK: Australia is definitely emerging as a biotechnology powerhouse. I am interested in covering Australian companies. but I am very aware of the differences ... Itesais goal to avoid some of the problems that micro-cap biotechnology stocks have seen in the U.S.. where if companies go public early. and are initially plagued with

https://www.justice.gov/epstein/files/DataSet%209/EFTA00956529.pdf

EFTA01915748Set 10

2012-12-044p925w

EFTA01915748 G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01915748.pdf

EFTA00949622Set 9

2012-12-043p867w

Officer G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US- Japan Science

https://www.justice.gov/epstein/files/DataSet%209/EFTA00949622.pdf

EFTA00718570Set 9

2012-12-043p936w

Officer G Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science

https://www.justice.gov/epstein/files/DataSet%209/EFTA00718570.pdf

EFTA00949627Set 9

2012-12-043p1,022w

Officer G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer ... Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. EFTA00949627 He currently serves on the Boards ... Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science

https://www.justice.gov/epstein/files/DataSet%209/EFTA00949627.pdf

EFTA01368503Set 10

2015-08-131p342w

request. PZM 08/13 20:05 Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program BFW 08/13 20:24 "AVALANCHE WON'T START ... AVALANCHE WON'T INITIATE PHASE 26 TRIAL BN 08/13 20:19 *AVALANCHE BIOTECHNOLOGIES 2Q REV $0.2M, EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR ... 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q'15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01368503.pdf

EFTA00586852Set 9

90p36,976w

Together, these changes will likely improve the return on invested capital of pharmaceutical and biotechnology companies. At the same time, drugs will likely be increasingly applicable to smaller subsets ... author of over 70 articles, patents and patent applications and co-founder of three biotechnology companies. Boris co-founded IMDx, Inc., which is focused on developing and distributing FDA approved ... major medical conditions (e.g. pneumonia, meningitis, septicemia, diarrhea). Boris co-founded Aquatrove, Inc., a biotechnology company focused on developing unique conception-promoting and infertility diagnostics products. He invented and developed

https://www.justice.gov/epstein/files/DataSet%209/EFTA00586852.pdf

EFTA01107676Set 9

2p667w

Analyst, Naxos UK Ltd. • Conducted pre-purchase analyses of internal and public documents of biotechnology firms as a part of Naxos's due diligence processes • CEO of Naxos followed ... full-time postgraduate degree in any subject available at the University of Cambridge. Biotechnology and Biological Sciences Research Council (BBSRC), PhD fellowship The BBSRC supports exceptional doctoral researchers to ensure ... flow of highly qualified people into careers in and outside of academia. Biotechnology Young Entrepreneurs Scheme (YES) Competition, BBSRC, 2011 • Runner up • Assembled and lead a team of five

https://www.justice.gov/epstein/files/DataSet%209/EFTA01107676.pdf

EFTA01206023Set 9

2015-08-143p736w

change without notice. Additional information is available upon request. PZM 08/13 20:05 Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program ... AVALANCHE WON'T INITIATE PHASE 2B TRIAL BN 08/13 20:19 *AVALANCHE BIOTECHNOLOGIES 2Q REV $0.2M, EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR ... 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q '15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy

https://www.justice.gov/epstein/files/DataSet%209/EFTA01206023.pdf

EFTA00848760Set 9

2015-08-143p650w

change without notice. Additional information is available upon request. PZM 08/13 20:05 Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program ... AVALANCHE WON'T INITIATE PHASE 2B TRIAL BN 08/13 20:19 *AVALANCHE BIOTECHNOLOGIES 2Q REV $0.2M, EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR ... 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q '15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy

https://www.justice.gov/epstein/files/DataSet%209/EFTA00848760.pdf

EFTA01412850Set 10

2015-08-144p585w

change without notice. Additional information is available upon request. --+ PZM 08/13 20:05 Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program ... AVALANCHE WON'T INITIATE PHASE 2B TRIAL BN 08/13 20:19 *AVALANCHE BIOTECHNOLOGIES 2Q REV $0.2M, EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR ... 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q '15 FINANCIAL RESULTS, --+ Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT EFTA01412851

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01412850.pdf